Managing Severe and Resistant Hypercholesterolemia: The Next Generation of LDL-C Lowering Agents
A CME-certified Program





Program Schedule


UCSF Chapter - Yosemite:  
Meeting Information: Faculty:
Date: Monday, October 17, 2016
Time: 12:30-1:30pm
Address: Yosemite Valley Lodge
9006 Yosemite Lodge Drive
Yosemite, CA 95389
Room Name: Cliff/Falls Room
Prakash Deedwania, MD, FACC, FAHA, FACP, FASH
Professor of Medicine
UCSF School of Medicine
San Francisco, CA
   
Georgia Chapter:  
Meeting Information: Faculty:
Date: Saturday, November 19, 2016
Time: 12:00 – 1:00 pm
Address: The Ritz-Carlton Lodge, Reynolds Plantation
1 Lake Oconee Trail
Greensboro, GA 30642
Michael Miller, MD, FACC, FAHA
Professor of Cardiovascular Medicine
Epidemiology and Public Healthe
University of Maryland School of Medicine
Staff Physician, Baltimore VAMC
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, MD
   
UCSF Chapter - San Francisco:  
Meeting Information: Faculty:
Date: Friday, December 16, 2016
Time: 12:00-1:00pm
Address: Park Central Hotel
50 Third Street
San Francisco, CA 94103
Room: Metropolitan Ballroom
Michael H. Davidson, MD, FACC, FNLA
Professor of Medicine
Director, Lipid Clinic
The University of Chicago Pritzker School of Medicine
Chicago, IL
   
Oregon Chapter:  
Meeting Information: Faculty:
Date: Friday, April 28, 2017
Time: 12:00 - 1:00 PM
Address: Sheraton Portland Airport Hotel
8235 Northeast Airport Way
Portland, OR 97220
Room: Mt. Adams
Michael H. Davidson, MD, FACC, FNLA
Professor of Medicine
Director, Lipid Clinic
The University of Chicago Pritzker School of Medicine
Chicago, IL
   
Illinois / Wisconsin Chapter:  
Meeting Information: Faculty:
Date: Saturday, May 6, 2017
Time: 7:30 - 8:30 AM
Address: Grand Geneva
7036 Grand Geneva Way
Lake Geneva, WI 53147
Room: Grand Ballroom
Michael H. Davidson, MD, FACC, FNLA
Professor of Medicine
Director, Lipid Clinic
The University of Chicago Pritzker School of Medicine
Chicago, IL

Presentation Slides

Download (PDF) Click here to view the presentation slides.

Program Description

New and emerging treatments to reduce low-density lipoprotein cholesterol (LDL-C) offer additional options to control cardiovascular disease (CVD) risk in patients who have severe or resistant hypercholesterolemia. There are a number of newly approved and emerging approaches which may be suitable for monotherapy or add-on therapy with statins. These include inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), inhibition of microsomal triglyceride transfer protein (MTP), and inhibition of apolipoprotein B-100 (apo-B) production.

This CME activity, Managing Severe and Resistant Hypercholesterolemia, will aid participating clinicians in applying evidence-based guidelines to appropriately manage their dyslipidemic patients who are at high risk for adverse cardiovascular events.


Agenda:

Welcome & Introduction
Treatment Guidelines and Pivotal Clinical Trial Data
Residual CVD Risk Despite Intensive Statin Therapy
Adjuncts/Alternatives to Statins to Lower LDL-C and Reduce Residual CVD Risk
Case Consult, Q&A Session and Activity Roundup

Target Audience

This activity is intended for community-based cardiologists, internal medicine specialists, and other healthcare providers who manage severely dyslipidemic patients at high risk for adverse cardiovascular events.


Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:
  • Describe the consequences of directing moderate to intense statin treatment to identified at-risk populations, rather than treating to LDL-C target goals
  • Evaluate extent of residual CVD risk to which high-risk dyslipidemic patients are exposed, and alter prescribing behavior to address additional CVD risk elements as appropriate
  • Analyze the potential strengths and weaknesses of new approaches to reduce CVD risk with new LDL-C lowering agents as stand-alone treatments or in combination with statins

Steering Committee



Michael Miller, MD, FACC, FAHA
Professor of Cardiovascular Medicine
Epidemiology and Public Health
University of Maryland School of Medicine
Staff Physician, Baltimore VAMC
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Baltimore, MD

Read Biography 

Peter P. Toth, MD, PhD
Director of Preventative Cardiology
CGH Medical Center
Sterling, IL
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, IL
Professor of Clinical Medicine
Michigan State University College of Osteopathic Medicine
East Lansing, MI
Adjunct Associate Professor Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

 Read Biography

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this live activity for a maximum 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email contact@potomacme.org.

Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will either be emailed within 2 weeks after submission of a completed evaluation form or distributed onsite.

There is no fee associated with this program.

SPECIAL SERVICES

 Event staff will be glad to assist you with any specials needs.  Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.

Provided by

 

Jointly provided by the Potomac Center for Medical Education and Rockpointe

     
     


supported by

     

This activity is supported by educational funding provided by Amgen.